{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:06:54Z","timestamp":1781737614843,"version":"3.54.5"},"reference-count":31,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2025,4,13]]},"DOI":"10.1080\/14656566.2025.2487150","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T04:02:21Z","timestamp":1743739341000},"page":"765-772","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of taletrectinib for treatment of ROS1 positive non-small cell lung cancer: A systematic review"],"prefix":"10.1080","volume":"26","author":[{"given":"Irtiqa","family":"Khan","sequence":"first","affiliation":[{"name":"School of Chemical & Life Sciences, Jamia Hamdard","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atiya","family":"Sahar","sequence":"additional","affiliation":[{"name":"School of Chemical & Life Sciences, Jamia Hamdard","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhaiba","family":"Numra","sequence":"additional","affiliation":[{"name":"School of Chemical & Life Sciences, Jamia Hamdard","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Saha","sequence":"additional","affiliation":[{"name":"School of Chemical & Life Sciences, Jamia Hamdard","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Nidhi","sequence":"additional","affiliation":[{"name":"School of Chemical & Life Sciences, Jamia Hamdard","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwana","family":"Parveen","sequence":"additional","affiliation":[{"name":"School of Chemical & Life Sciences, Jamia Hamdard","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002529"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.4065\/83.5.584"},{"key":"e_1_3_6_5_1","article-title":"Non\u2013small cell lung cancer","author":"Clark SB","year":"2025","unstructured":"Clark SB, Alsubait S. Non\u2013small cell lung cancer. In: StatPearls. [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan [updated 2023 Sep 4]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562307\/","journal-title":"StatPearls"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12359"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11783"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.196"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01069-z"},{"key":"e_1_3_6_10_1","article-title":"Tyrosine kinase inhibitors","author":"Thomson RJ","year":"2025","unstructured":"Thomson RJ, Moshirfar M, Ronquillo Y. Tyrosine kinase inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan [updated 2023 Jul 18]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563322\/","journal-title":"StatPearls"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.04.022"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00881-7"},{"issue":"148","key":"e_1_3_6_13_1","first-page":"167","article-title":"Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update","volume":"27","author":"Jonna S","year":"2019","unstructured":"Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. Discov Med. 2019 Mar 28;27(148):167\u2013170.","journal-title":"Discov Med"},{"key":"e_1_3_6_14_1","volume-title":"AnHeart therapeutics and foundation medicine announce collaboration to develop tissue-based and liquid-based companion diagnostics for taletrectinib, a ROS1 inhibitor |","year":"2023","unstructured":"AnHeart therapeutics and foundation medicine announce collaboration to develop tissue-based and liquid-based companion diagnostics for taletrectinib, a ROS1 inhibitor |. New York: AnHeart Therapeutics; 2023 [cited 2025 Feb 20]. Available from: https:\/\/www.foundationmedicine.com\/press-release\/anheart-therapeutics-and-foundation-medicine-announce-collaboration"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8572"},{"key":"e_1_3_6_16_1","unstructured":"FDA grants breakthrough therapy designation to taletrectinib for ROS1+ NSCLC. New York: 2025 Mar 05. Available from: https:\/\/investors.nuvationbio.com\/news\/news-details\/2025\/Nuvation-Bio-Announces-Expanded-Access-Program-in-the-U.S.-for-Taletrectinib-in-Advanced-ROS1-positive-Non-Small-Cell-Lung-Cancer\/default.aspx"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2024.2305131"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100332"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(22)00812-7"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30655-2"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027187"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00731"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1630"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100673"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11496-z"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25263"},{"key":"e_1_3_6_27_1","unstructured":"A phase III study comparing taletrectinib with standard therapy in ROS1 positive locally advanced or metastatic non-small cell lung cancer patients (NCT06564324). In: Clinicaltrials.gov [Internet]. Nuvation Bio Inc; [cited 2025 Mar]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06564324?term=taletrectinib&rank=4"},{"key":"e_1_3_6_28_1","unstructured":"Taletrectinib phase 2 global study in ROS1 positive NSCLC (TRUST-II) (NCT04919811). In: Clinicaltrials.gov [Internet]. Nuvation Bio Inc; [cited 2025 Feb]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04919811?term=taletrectinib&rank=1"},{"key":"e_1_3_6_29_1","unstructured":"Taletrectinib in Previously treated metastatic CDH1-mutated invasive lobular cancer (ILC) (NCT06214793). In: Clinicaltrials.gov [Internet]. Megan Kruse; [cited 2025 Feb]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06214793?term=taletrectinib&rank=2"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-1059"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8601"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100108"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-IO-S1-s02"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2025.2487150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T04:08:07Z","timestamp":1744603687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2025.2487150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,4,13]]}},"alternative-id":["10.1080\/14656566.2025.2487150"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2025.2487150","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}